Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors-Reference-Cited by-同舟云学术

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Published:2019-01 Issue: Volume:107 Page:8-14
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hasan Ali Omar,Berner Fiamma,Bomze David,Fässler Mirjam,Diem Stefan,Cozzio Antonio,Jörger Markus^ORCID,Früh Martin^ORCID,Driessen Christoph,Lenz Tobias L.,Flatz Lukas

Funder

Swiss National Science Foundation

German Research Foundation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

2. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Is autoimmunity the Achilles' heel of cancer immunotherapy?;June;Nat Med,2017

4. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma;Weber;Cancer,2013

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy;Cancers;2024-09-07

2. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors;World Journal of Clinical Oncology;2024-08-24

3. Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report;Frontiers in Immunology;2024-07-05

4. Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors;Journal for ImmunoTherapy of Cancer;2024-07

5. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07